Two-stage design for dose-finding that accounts for both efficacy and safety.
We introduce a two-stage design for dose-finding in the context of Phase I/II studies, where two binary correlated endpoints are available, for instance, one for efficacy and one for toxicity. The bivariate probit model is used as a working model for the dose-response relationship. Given a 'desirable point' for the marginal probabilities of efficacy and toxicity, the goal is to find the target dose that is 'closest' to the desirable point. The criterion of optimality (objective function) is the variance of the estimator for that dose. Optimal experimental design methodology is used to construct efficient dose allocation procedures that treat patients in the study at doses that are both safe and efficacious.
Dragalin
Vladimir
V
Wyeth Pharmaceuticals, Collegeville, PA, USA.
Fedorov
Valerii V
VV
Wu
Yuehui
Y
D000465:Algorithms; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008508:Medication Errors / Q000517:prevention & control; D012107:Research Design; D017751:Safety Management; D016896:Treatment Outcome